$3.620
+0.051 (+1.40%)收盘时
GDRX 资讯
GDRX 事件
GoodRx Launches Family Plan for $24.99 Monthly
GoodRx launched the GoodRx Companion Family Plan, expanding its everyday healthcare subscription to the entire family, including pets. As widening coverage gaps and rising out-of-pocket costs leave households paying more for care, the new plan brings Companion's free and low-cost prescriptions and savings on common healthcare services together in one affordable, predictably priced membership. The Companion Family Plan, which costs $24.99 per month or $16.99 per month when paying annually, extends Companion benefits to a primary member and up to four dependents, which may include children, adult family members, and pets. Members can access more than 250 eligible generic medications for free and hundreds more for under $10 at nearly every pharmacy nationwide, plus savings on dental, vision, lab and imaging services. The primary member also receives access to $19 online care visits. Together, these features give families an affordable and predictable way to save across prescriptions and common healthcare needs.
GoodRx Q2 Revenue $200.4M, Exceeds Consensus
Reports Q2 revenue $200.4M, consensus $193.16M. "We entered 2026 focused on scaling Pharma Direct and subscriptions, and the second quarter provided clear evidence that those investments are translating into stronger performance," said Wendy Barnes, President and Chief Executive Officer of GoodRx. "We believe this progress is accelerating our return to growth and strengthening the long-term durability of GoodRx."
Raises FY26 Adjusted EBITDA Outlook to $240M-$250M
Consensus $775.88M. Raises FY26 adjusted EBITDA view to $240M-$250M from over $235M.
GoodRx Launches GoodRx Companion Subscription at $14.99 per Month
GoodRx launched GoodRx Companion, a new $14.99-per-month subscription. "GoodRx Companion is an important step in our evolution toward building a broader subscription model built for the way consumers are navigating healthcare today," said Wendy Barnes, President and CEO of GoodRx. "As coverage becomes more complex and out-of-pocket costs continue to rise, people are looking for trusted solutions that give them greater control and clearer value. Companion meets that demand while advancing our strategy to build deeper, more recurring consumer relationships across a growing portfolio of subscription offerings. This is where we believe the market is headed, and where we believe GoodRx is uniquely positioned to lead."
Raises FY26 Adjusted EBITDA Outlook to Over $235M
Consensus $764.78M. Raises FY26 adjusted EBITDA view to over $235M from over $230M.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。